公开(公告)号：US08076503B2

公开(公告)日：2011-12-13

申请号：US12298067

申请日：2007-09-03

申请人： Nobuto Minowa ,  Nozomu Nakanishi ,  Masaaki Mitomi ,  Hideki Nara ,  Tohru Yokozawa

发明人： Nobuto Minowa ,  Nozomu Nakanishi ,  Masaaki Mitomi ,  Hideki Nara ,  Tohru Yokozawa

IPC分类号： C07C229/04 ,  C07F9/28

CPC分类号： C07B53/00 ,  C07F9/301 ,  C07F9/3211

摘要： The present invention is a process for producing optically active aminophosphinylbutanoic acids represented by the formula (2), comprising asymmetrically hydrogenating a compound represented by the formula (1) in the presence of a ruthenium-optically active phosphine complex, a process for the production thereof, and a compound useful in a herbicide such as L-AHPB that can be produced with good efficiency and high asymmetric yield.

摘要翻译： 本发明是一种制备由式（2）表示的光学活性氨基氧膦基丁酸的方法，包括在钌 - 光学活性膦配合物的存在下不对称地氢化由式（1）表示的化合物，其制备方法 ，以及可以以高效率和高不对称产率生产的用于除草剂如L-AHPB的化合物。

公开(公告)号：US20110294192A1

公开(公告)日：2011-12-01

申请号：US13129969

申请日：2009-11-06

申请人： Takayoshi Fukushima ,  Kengo Yokoyama ,  Koichiro Murashima ,  Masafumi Goto ,  Youhei Yamagata

发明人： Takayoshi Fukushima ,  Kengo Yokoyama ,  Koichiro Murashima ,  Masafumi Goto ,  Youhei Yamagata

IPC分类号： C12N9/52

CPC分类号： C07K14/78 ,  C07K2319/21 ,  C12N9/52

摘要： A fusion collagenase in which an affinity tag is added to the carboxyl terminal of a collagenase was expressed as a recombinant protein. It was found that a collagenase having a collagen-binding domain can be selectively collected by purifying the obtained fusion collagenase by affinity chromatography.

摘要翻译： 其中将亲和标签添加到胶原酶的羧基末端的融合胶原酶被表达为重组蛋白。 发现通过亲和层析纯化获得的融合胶原酶，可以选择性地收集具有胶原结合结构域的胶原酶。

公开(公告)号：US12103928B2

公开(公告)日：2024-10-01

申请号：US18199019

申请日：2023-05-18

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： Takao Abe ,  Takeshi Furuuchi ,  Yoshiaki Sakamaki

IPC分类号： C07D471/08 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/427 ,  A61K31/43 ,  A61K31/437 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/545 ,  A61K31/546 ,  A61K45/06 ,  C07D211/60 ,  C07F7/08

CPC分类号： C07D471/08 ,  A61K31/407 ,  A61K31/4162 ,  A61K31/427 ,  A61K31/43 ,  A61K31/437 ,  A61K31/439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/545 ,  A61K31/546 ,  A61K45/06 ,  C07D211/60 ,  C07F7/0812 ,  Y02P20/55 ,  A61K31/43 ,  A61K2300/00 ,  A61K31/545 ,  A61K2300/00 ,  A61K31/546 ,  A61K2300/00 ,  A61K31/407 ,  A61K2300/00 ,  A61K31/4162 ,  A61K2300/00 ,  A61K31/427 ,  A61K2300/00 ,  A61K31/439 ,  A61K2300/00 ,  A61K31/4545 ,  A61K2300/00 ,  A61K31/5377 ,  A61K2300/00

摘要： A process for preparing a diazabicyclooctane compound represented by the following formula (I):




wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c):





wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.

公开(公告)号：US20240317859A1

公开(公告)日：2024-09-26

申请号：US18290006

申请日：2022-05-12

申请人： FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION ,  MEIJI SEIKA PHARMA CO., LTD.

发明人： Tasuku HONJO ,  Akio OHTA ,  Masaki TAJIMA ,  Haruhiko KAMADA ,  Satoshi NAGATA ,  Kensuke SUZUKI ,  Takayoshi FUKUSHIMA ,  Yosuke TOKUMARU

IPC分类号： C07K16/28

CPC分类号： C07K16/2818 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52

摘要： Conditions necessary for antibodies to human PD-1 to have agonist activity are searched and an optimized agonist antibody is provided based on the conditions and used as a therapeutic for human inflammatory diseases. An agonist antibody to human PD-1 or a functional fragment thereof, wherein the antibody or a functional fragment thereof binds to domain #7 of human PD-1 as shown in SEQ ID NO: 9 is provided.

公开(公告)号：US11414417B2

公开(公告)日：2022-08-16

申请号：US16793843

申请日：2020-02-18

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： Takao Abe ,  Takeshi Furuuchi ,  Yoshiaki Sakamaki ,  Nakako Mitsuhashi ,  Yumiko Saito

IPC分类号： C07D471/08 ,  A61K31/439 ,  A61K45/06

摘要： A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 Å in the powder X-ray diffraction pattern.

公开(公告)号：US20220098290A1

公开(公告)日：2022-03-31

申请号：US17434619

申请日：2020-02-28

申请人： JUNTENDO EDUCATIONAL FOUNDATION ,  MEIJI SEIKA PHARMA CO., LTD.

发明人： Marito ARAKI ,  Yoshihiko KIHARA ,  Norio KOMATSU

IPC分类号： C07K16/18 ,  G01N33/574 ,  G01N33/50

摘要： A diagnostic, preventive, or therapeutic agent may be used for a myeloproliferative neoplasm. An antibody or a functional fragment thereof that binds to a cleaved mutant CALR protein, may include an antigen-recognition site in (a) a polypeptide chain having an amino acid sequence set forth in SEQ ID NO: 1 or (b) a polypeptide chain having an amino acid sequence having deletion, substitution, or addition of one to several amino acids in SEQ ID NO: 1; and a diagnostic, preventive, or therapeutic agent for a myeloproliferative neoplasm containing the antibody.

公开(公告)号：US11117895B2

公开(公告)日：2021-09-14

申请号：US16297550

申请日：2019-03-08

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： Takaya Ogawa ,  Takuya Yokoyama ,  Shusuke Furuyama ,  Masato Ichiki ,  Kenichi Fushihara

IPC分类号： C07D471/08 ,  A61K9/19 ,  A61K31/439 ,  A61K47/02 ,  A61K9/00

摘要： A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.

公开(公告)号：US20210155630A1

公开(公告)日：2021-05-27

申请号：US17255584

申请日：2019-06-27

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： KO KUMURA ,  KEIJI TAMURA ,  TAKASHI WATANABE ,  MICHIKO TAKAHASHI

IPC分类号： C07D487/08

摘要： Provided are crystals of 1-((2-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-7-(thiazol-2-yl)benzo[d]oxazol-4-yl)oxy)-1,1-difluoro-2-methylpropan-2-ol represented by formula (1),

公开(公告)号：US10576094B2

公开(公告)日：2020-03-03

申请号：US15747581

申请日：2016-07-29

申请人： MICROBIAL CHEMISTRY RESEARCH FOUNDATION ,  MEIJI SEIKA PHARMA CO., LTD.

发明人： Yoshiaki Takahashi ,  Eijiro Umemura ,  Takashi Ida ,  Masayuki Igarashi

IPC分类号： A61K31/7036 ,  C07H15/224 ,  A61P31/04

摘要： A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.

公开(公告)号：US20190270709A1

公开(公告)日：2019-09-05

申请号：US16333712

申请日：2017-09-15

申请人： MEIJI SEIKA PHARMA CO., LTD.

发明人： Shigeki KITSUDA ,  Nozomu NAKANISHI ,  Shinjiro SUMI

IPC分类号： C07D213/75 ,  A01N47/40

摘要： The present invention provides a method for producing a compound represented by the following formula (I) with a compound represented by the following formula (A) as a starting substance via production of an intermediate represented by the following formula (B) by use of a trifluoroacetic acid ester and a metal base.